Compare Adaptive Biotechnologies Corp (ADPT) vs American States Water Company (AWR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs American States Water Company — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while American States Water Company trades at $84.03 (market cap $3.26B). The key difference: Adaptive Biotechnologies Corp and American States Water Company are close in size by market cap, and American States Water Company pays a 2.42% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | AWR | |
|---|---|---|
Market Cap | $3.33B | $3.26B |
Sector | Health | Utilities |
52-Week High | $22.37 | $84.76 |
52-Week Low | $10.24 | $70.10 |
Enterprise Value | $3.19B | $4.17B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
American States Water (AWR) trades at $83.14, down 1.91% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 19.66% net margins and consistent dividend growth, though recent earnings show mixed quarterly performance. Recent news highlights AWR's defensive utility characteristics and completion of a $200 million equity offering program.
AWR presents a stable investment case with reliable dividend income and utility sector defensiveness, though valuation appears elevated at 24.24 P/E. Key risks include regulatory rate pressures and execution of capital investments. Analyst sentiment remains cautious with only 20% buy ratings, suggesting limited near-term upside potential despite the company's operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →
